、多因素驱动下游需求旺盛，中上游有望率先获益证券研究报告/行业深度报告医药生物2023年10月16日[评Ta级ble：_T增itle持]（维持）[重Ta点ble公_F司in基anc本e]状况分析师：祝嘉琦简称股价EPSPEPEG评级执业证书编号：S07405190400012023E2024E电话：021-20315150(元)20222023E2024E2025E202227.2821.432025E0.98买入Email：zhujq@zts.com.cn5.40A30.3725.5124.9316.691.50买入分析师：崔少煜药明康德90.18A2.973.314.218.4317.5961.0750.9518.633.07买入执业证书编号：S0740522060001凯莱英1.0572.9124.9720.0242.491.05买入Email：cuisy@zts.com.cn157.158.936.166.302.6129.8532.0324.5816.280.91买入0.9541.7839.3330.1817.531.31买入恒瑞医药44.650.610.730.881.1049.2323.230.60买入1.4610.047.586.735.981.9...